ArticleEuropean journal of heart failure2020
Myocardial dysfunction in long-term breast cancer survivors treated at ages 40-50 years.
Article in European journal of heart failure, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 39 citations in OpenAlex.
- Prevalence of cardiac dysfunction and longitudinal changes in cardiac function after breast cancer treatment with chemotherapy with/without radiation therapy compared with controls.Breast (Edinburgh, Scotland) · 2026Observational
- Association between systemic inflammation and risk of atrial fibrillation in cancer survivors: a population-based cohort study using UK biobank.Cardio-oncology (London, England) · 2025Article
- Surveillance of left ventricular function among cancer survivors.Heart (British Cardiac Society) · 2025Article
- Effects of an Easily Implemented Physical Exercise Program on the Ventricular Ejection Fraction of Women with Breast Cancer Undergoing Chemotherapy.International journal of environmental research and public health · 2025Article
- Cardiorespiratory fitness, cardiac morphology and function, and cardiovascular risk factors in long-term breast cancer survivors compared with non-cancer controls.Cardio-oncology (London, England) · 2025Article
- Article
- Diastolic dysfunction and risks of heart failure and death in long-term adult cancer survivors.BMC medicine · 2024Article
- Review
- Endothelin-based markers for endothelial dysfunction in chemotherapy-induced cardiotoxicity.Journal of molecular and cellular cardiology plus · 2023Review
- Detection of right ventricular dysfunction by three - dimensional echocardiography and two - dimensional speckle tracking in breast cancer patients receiving anthracycline- based chemotherapy.Cardio-oncology (London, England) · 2023Article
- Recent Advances in Serum Biomarkers for Risk Stratification and Patient Management in Cardio-Oncology.Current cardiology reports · 2023Review
- Global longitudinal strain: an early marker for cardiotoxicity in patients treated for breast cancer.Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation · 2023Article
- Supervised exercise training in patients with cancer during anthracycline-based chemotherapy to mitigate cardiotoxicity: a randomized-controlled-trial.Frontiers in cardiovascular medicine · 2023Article
- Adjuvant aromatase inhibitor therapy and early markers for cardiovascular disease in breast cancer survivors.Breast cancer research and treatment · 2022Article
- Heart failure: an update from the last years and a look at the near future.ESC heart failure · 2022Review
- Physical Activity and Cardiac Function in Long-Term Breast Cancer Survivors: A Cross-Sectional Study.JACC. CardioOncology · 2022Article
- Article
- Additive Effects of Obesity on Myocardial Microcirculation and Left Ventricular Deformation in Essential Hypertension: A Contrast-Enhanced Cardiac Magnetic Resonance Imaging Study.Frontiers in cardiovascular medicine · 2022Article
- Early Predictive Value of NT-proBNP Combined With Echocardiography in Anthracyclines Induced Cardiotoxicity.Frontiers in surgery · 2022Article
- A year in heart failure: an update of recent findings.ESC heart failure · 2021Review
Corrections and comments
- Commented on by
Authors and funding
13 authors at 3 institutions in 1 country.
Funding
Abstract
aimsAnthracyclines increase heart failure (HF) risk, but the long-term prevalence of myocardial dysfunction in young breast cancer (BC) survivors is unknown. Early measures of left ventricular myocardial dysfunction are needed to identify BC patients at risk of symptomatic HF. METHODS AND
resultsWithin an established cohort, we studied markers for myocardial dysfunction among 569 women, who were 5-7 years (n = 277) or 10-12 years (n = 292) after BC treatment at ages 40-50 years. Left ventricular ejection fraction (LVEF) and global longitudinal strain (GLS) were assessed by echocardiography. N-terminal pro-brain natriuretic peptide (NT-proBNP) was measured in serum. Associations between patient-related and treatment-related risk factors and myocardial dysfunction were evaluated using linear and logistic regression. Median ages at BC diagnosis and cardiac assessment were 46.7 and 55.5 years, respectively. Anthracycline-treated patients (n = 313), compared to the no-anthracycline group (n = 256), more often had decreased LVEF (10% vs. 4%), impaired GLS (34% vs. 27%) and elevated NT-proBNP (23% vs. 8%). GLS and LVEF declined in a linear fashion with increasing cumulative anthracycline dose (GLS: +0.23 and LVEF: -0.40 per cycle of 60 mg/m
conclusionImpaired GLS and increased NT-proBNP levels are present in a substantial proportion of young BC survivors treated with anthracyclines. Whether this will lead to future cardiac disease needs to be evaluated by longitudinal assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.